Clinical trial
Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic…
NCT00455910 · Groupe Francophone des Myelodysplasies, Other · Completed
Key facts
| NCT number | NCT00455910 |
|---|---|
| Title | Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200 |
| Official title | Thalidomide for the Treatment of Cytopenias of Patients With Low Risk Myelodysplastic Syndromes |
| Lead sponsor | Groupe Francophone des Myelodysplasies, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | Thalidomide |
| Enrollment | 112 |
| Start date | Jan 1, 2003 |
| Completion | Mar 1, 2007 |
| First posted | Apr 4, 2007 |
| Last update posted | Apr 4, 2007 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: